PVLA
Palvella Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$124.15-21.04%
Price as of Jul 20, 2026
PVLA financials
Palvella Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $25.9M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $2.8M |
| Gross profit | $0.00 | $0.00 | $0.00 | $23.1M |
| Operating expenses | $38.6M | $14.1M | $11.9M | $66.6M |
| Operating income | -$38.6M | -$14.1M | -$11.9M | -$43.5M |
| Net income | -$41.7M | -$17.4M | $18.7M | -$33.3M |
| EBITDA | -$35.9M | -$13.1M | $18.7M | -$30.5M |
| Basic EPS | $-3.71 | $-7.83 | $14.74 | $-29.61 |
| Diluted EPS | $-3.71 | $-7.83 | $14.74 | $-29.61 |
| Balance sheet | ||||
| Cash & equivalents | $58.0M | $83.6M | $7.3M | $16.1M |
| Total assets | $59.6M | $88.2M | $7.5M | $16.5M |
| Total liabilities | $31.6M | $25.6M | $11.4M | $39.7M |
| Stockholders’ equity | $28.0M | $62.6M | -$3.9M | -$23.2M |
| Total debt | $633.0K | $0.00 | $0.00 | $0.00 |
| Net debt | -$57.3M | -$83.6M | -$7.3M | -$16.1M |
| Cash flow | ||||
| Operating cash flow | -$25.0M | -$10.8M | -$13.7M | -$14.8M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$25.0M | -$10.8M | -$13.7M | -$14.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |